# Olatorepatide: Regeneron's GLP-1/GIP drug, known so far

Source: https://pepvault.app/guides/olatorepatide-explained

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [GLP-1s](https://pepvault.app/guides#glp1)

# Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far

Reviewed November 2026 19 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

Olatorepatide (HS-20094) is a weekly GLP-1/GIP shot from Hansoh, licensed to Regeneron: the 19.3% phase 3 result, every trial, and when US data is due.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 19
- **Questions:** 6
- **Compounds:** 2

## The short answer

Olatorepatide (code name HS-20094) is a once-weekly GLP-1/GIP injection, the same drug class as Zepbound. China's Hansoh Pharma invented it and Regeneron holds the rights outside China. In Hansoh's 48-week phase 3 trial in 604 Chinese adults, weight fell 19.3% on the 15 mg dose, against 2.7% on placebo. It is approved nowhere; Regeneron's US trials are under way.

Every number checked at its primary source · Nov 20, 2026 · [19 sources](https://pepvault.app/guides/olatorepatide-explained#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** Early to mid-stage: one completed phase 3 trial in Chinese adults, reported in Hansoh's conference releases with no journal paper yet, plus small phase 2 diabetes data; Regeneron's US trials have no results. Approved nowhere.

## What is olatorepatide?

Olatorepatide is an experimental weight-loss and diabetes injection taken once a week. It switches on two hormone receptors at once: GLP-1 and GIP, the two gut hormones that help set appetite and blood sugar after a meal. That makes it a dual agonist, the class tirzepatide (Zepbound, Mounjaro) opened.

Hansoh Pharma, a Shanghai drug company, discovered it in house and ran its trials as **HS-20094** [2](https://pepvault.app/guides/olatorepatide-explained#source-2) [6](https://pepvault.app/guides/olatorepatide-explained#source-6). **Olatorepatide** is its generic name, the international nonproprietary name (INN) the World Health Organization proposed in List 130, which names it a dual GIP and GLP-1 receptor agonist[1](https://pepvault.app/guides/olatorepatide-explained#source-1). Regeneron, the New York company best known for Dupixent and Eylea, uses the INN and lists the drug as in-licensed from Hansoh[4](https://pepvault.app/guides/olatorepatide-explained#source-4).

The deal was announced on June 2, 2025: Regeneron took the rights everywhere except mainland China, Hong Kong and Macau for $80 million up front, with up to $1.93 billion more in milestone payments and double-digit royalties on sales[2](https://pepvault.app/guides/olatorepatide-explained#source-2). Regeneron's filings say the license took effect in July 2025 and the royalty is low double-digit[3](https://pepvault.app/guides/olatorepatide-explained#source-3) [4](https://pepvault.app/guides/olatorepatide-explained#source-4). Hansoh keeps China, where its application for approval was accepted for review in June 2026[9](https://pepvault.app/guides/olatorepatide-explained#source-9).

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

PepVault keeps your weekly shot and your weigh-ins side by side, so your own trend line is there to compare with any trial's.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## How does olatorepatide work?

Like tirzepatide, it lowers appetite so people eat less, slows how fast the stomach empties and helps the pancreas release insulin[10](https://pepvault.app/guides/olatorepatide-explained#source-10). The WHO entry shows how closely it is built on the same plan[1](https://pepvault.app/guides/olatorepatide-explained#source-1) [18](https://pepvault.app/guides/olatorepatide-explained#source-18):

- **A chain of 40 amino acids**, one longer than tirzepatide's 39, with the same unusual second building block tirzepatide uses (Aib), which helps the peptide resist the enzyme that breaks down the body's own GLP-1 within minutes[1](https://pepvault.app/guides/olatorepatide-explained#source-1) [18](https://pepvault.app/guides/olatorepatide-explained#source-18).
- **A 20-carbon fatty acid** fixed to its last amino acid through a short linker. Tirzepatide carries the same fatty acid on its 20th amino acid, and there it makes the drug ride on albumin, a blood protein, so the body clears it slowly; olatorepatide's tail is built for the same job[1](https://pepvault.app/guides/olatorepatide-explained#source-1) [18](https://pepvault.app/guides/olatorepatide-explained#source-18).
- **A half-life of about six to seven days**, the time the body takes to clear half a dose: 142 to 168 hours in Hansoh's early diabetes trial[10](https://pepvault.app/guides/olatorepatide-explained#source-10), against about five to six days for tirzepatide[18](https://pepvault.app/guides/olatorepatide-explained#source-18). That is what makes one shot a week enough.

Hansoh calls olatorepatide "dual-biased"[7](https://pepvault.app/guides/olatorepatide-explained#source-7). A biased agonist switches a receptor on in a chosen way, usually sending the receptor's main signal while pulling in less of beta-arrestin, the protein that dulls a receptor and draws it into the cell. Hansoh presents the design as the way olatorepatide pairs strong weight loss with easier tolerability[7](https://pepvault.app/guides/olatorepatide-explained#source-7); it has not published which signals the drug favours, so the claim stands as the company's.

## How much weight did people lose on olatorepatide?

Up to 19.3% in 48 weeks, and still falling. LIGHTEN, Hansoh's phase 3 trial, gave 604 Chinese adults a weekly shot of 5, 10 or 15 mg or placebo for 48 weeks; people qualified with a BMI of 28 or more, or 24 to 28 with a weight-related condition[7](https://pepvault.app/guides/olatorepatide-explained#source-7) [11](https://pepvault.app/guides/olatorepatide-explained#source-11). Of them, 90.1% finished the full 48 weeks, and up to 97.2% of those on the drug lost at least 5% of their weight[6](https://pepvault.app/guides/olatorepatide-explained#source-6) [7](https://pepvault.app/guides/olatorepatide-explained#source-7). The trial met both of its main goals, average weight change and the share who lost at least 5%[6](https://pepvault.app/guides/olatorepatide-explained#source-6).

| LIGHTEN, week 48 | Placebo | 5 mg | 10 mg | 15 mg |
| --- | --- | --- | --- | --- |
| Weight change, while on treatment[7](https://pepvault.app/guides/olatorepatide-explained#source-7) | -2.7% | -12.5% | -17.5% | -19.3% |
| Weight change, counting everyone who started[7](https://pepvault.app/guides/olatorepatide-explained#source-7) | -2.5% | -11.8% | -17.0% | -18.7% |

The two weight rows answer different questions. The first follows people while they kept taking the drug; the second counts everyone who started, including those who stopped, which is closer to real life. On 15 mg the waist shrank by 16.0 cm on average. Hansoh reports that the weight curve had not flattened at week 48[7](https://pepvault.app/guides/olatorepatide-explained#source-7), and that blood pressure, blood fats, HbA1c (the three-month blood sugar average) and insulin resistance improved too[7](https://pepvault.app/guides/olatorepatide-explained#source-7).

The fairest yardstick is tirzepatide's own trial in China. SURMOUNT-CN enrolled Chinese adults on the same BMI rules, without diabetes, for 52 weeks: weight fell 17.5% on 15 mg tirzepatide and 2.3% on placebo, counting everyone[17](https://pepvault.app/guides/olatorepatide-explained#source-17). Olatorepatide reached 18.7% by the same count four weeks sooner, 16.2 points beyond its placebo against tirzepatide's 15.2. Our reading: in Chinese adults it is level with tirzepatide or a little ahead. The two were never tested against each other, so this is a close call, not a verdict.

A sex-subgroup analysis shown at ObesityWeek on November 14, 2026, found that women did numerically better than men on weight, waist, waist-to-height ratio and a fatty-liver score, and more of them reached 15% and 20% weight loss[8](https://pepvault.app/guides/olatorepatide-explained#source-8). Hansoh has not yet published LIGHTEN in a journal; the numbers above come from its conference releases.

<!--promo-->

PepVault keeps your weekly shot and your weigh-ins side by side, so your own trend line is there to compare with any trial's. [Track your weight in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-olatorepatide-explained-inline&mt=8)

<!--/promo-->

## With this guide

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Mixing charts

- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)
- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)

### Studies

- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)
- [Semaglutide: 11.85% more weight loss than placebo without diabetes](https://pepvault.app/research/semaglutide-tan-2022)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 31 studies](https://pepvault.app/research#semaglutide)

### Compared with

- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Mazdutide vs Tirzepatide](https://pepvault.app/peptides/compare/mazdutide-vs-tirzepatide)
- [Tirzepatide vs Liraglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-liraglutide)
- [Tirzepatide vs Dulaglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-dulaglutide)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Amino acid](https://pepvault.app/glossary/amino-acid)
- [Receptor agonist](https://pepvault.app/glossary/receptor-agonist)
- [Unit (on a syringe)](https://pepvault.app/glossary/syringe-units)
- [Half-life](https://pepvault.app/glossary/half-life)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)
- [Placebo](https://pepvault.app/glossary/placebo)

## What side effects did olatorepatide cause?

The usual ones for this class, in the stomach and gut, and at well under the rates tirzepatide showed in its own trial in Chinese adults. Olatorepatide's figures are averaged across the three LIGHTEN doses[7](https://pepvault.app/guides/olatorepatide-explained#source-7); tirzepatide's are the range across its 10 and 15 mg doses in SURMOUNT-CN[17](https://pepvault.app/guides/olatorepatide-explained#source-17):

| Side effect | Olatorepatide, LIGHTEN[7](https://pepvault.app/guides/olatorepatide-explained#source-7) | Placebo, LIGHTEN[7](https://pepvault.app/guides/olatorepatide-explained#source-7) | Tirzepatide, SURMOUNT-CN[17](https://pepvault.app/guides/olatorepatide-explained#source-17) | Placebo, SURMOUNT-CN[17](https://pepvault.app/guides/olatorepatide-explained#source-17) |
| --- | --- | --- | --- | --- |
| Nausea | 7.8% | 2.6% | 30.0% to 32.4% | 5.8% |
| Vomiting | 4.9% | 2.0% | 11.4% to 19.7% | 4.3% |
| Diarrhea | 16.9% | 7.8% | 40.0% to 40.8% | 8.7% |
| Constipation | 5.1% | 1.3% | Under 10% | Under 10% |

No one in LIGHTEN stopped treatment or left the trial early because of a side effect judged to be caused by olatorepatide[7](https://pepvault.app/guides/olatorepatide-explained#source-7); in SURMOUNT-CN, 2.9% to 7.0% stopped tirzepatide for a side effect[17](https://pepvault.app/guides/olatorepatide-explained#source-17). Nausea came in 9.0% of women and 5.0% of men on olatorepatide[8](https://pepvault.app/guides/olatorepatide-explained#source-8). Zepbound's US label, from trials mostly outside China, lists nausea at 25% to 29%[18](https://pepvault.app/guides/olatorepatide-explained#source-18). The gap is wide, and Regeneron's US trials will show whether it holds in a different population.

**When to get help** On any GLP-1 drug, severe stomach pain that will not ease, sometimes reaching the back, or vomiting that stops you keeping fluids down is a reason to call your clinician the same day[18](https://pepvault.app/guides/olatorepatide-explained#source-18).

## Which olatorepatide trials are in the registry?

Twelve records name it under either name as of November 20, 2026, eight sponsored by Hansoh in China and four by Regeneron, whose three trials with sites listed are all in the United States[16](https://pepvault.app/guides/olatorepatide-explained#source-16). Dates are primary completion, per ClinicalTrials.gov: when the main measurement ends, not when results come out. "Est." marks the sponsor's estimate.

| Trial | Phase | People | Primary completion | Status |
| --- | --- | --- | --- | --- |
| Regeneron, US: weight, safety and blood levels (NCT07431086)[12](https://pepvault.app/guides/olatorepatide-explained#source-12) | 2 | 120 | Nov 13, 2026 (est.) | Active, not recruiting |
| Regeneron, US: doses and step-up schedules, 52 weeks (NCT07685808)[13](https://pepvault.app/guides/olatorepatide-explained#source-13) | 2 | 360 (planned) | Jan 2028 (est.) | Recruiting |
| Regeneron, hidradenitis suppurativa with obesity (NCT07830329)[15](https://pepvault.app/guides/olatorepatide-explained#source-15) | 2 | 300 (planned) | Nov 2028 (est.) | Recruiting |
| Regeneron, RISE-1: obesity without diabetes, 72 weeks (NCT07896265)[14](https://pepvault.app/guides/olatorepatide-explained#source-14) | 3 | 3,000 (planned) | Dec 2028 (est.) | Not yet recruiting |
| Hansoh, LIGHTEN: obesity, China (NCT06839664)[11](https://pepvault.app/guides/olatorepatide-explained#source-11) | 3 | 604 | Jan 2026 | Completed |
| Hansoh, type 2 diabetes vs dulaglutide, China (NCT07156539) | 3 | 546 (planned) | Mar 2027 (est.) | Not yet recruiting (record from Sep 2025) |
| Hansoh, type 2 diabetes on diet and exercise, China (NCT07156500) | 3 | 204 (planned) | Mar 2027 (est.) | Not yet recruiting (record from Sep 2025) |
| Hansoh, obesity, 24 weeks, China (NCT06118021) | 2 | 200 | Aug 2024 | Completed, no results posted |
| Hansoh, type 2 diabetes vs dulaglutide, 32 weeks, China (NCT06901648) | 2 | 275 | Mar 2025 | Completed, no results posted |
| Hansoh, type 2 diabetes, 4 weeks, China (NCT06118008)[10](https://pepvault.app/guides/olatorepatide-explained#source-10) | 2 | 54 | Jan 2024 | Completed |
| Hansoh, two pen types, China (NCT07057674) | 1 | 144 (planned) | Feb 2026 (est.) | Recruiting (record from Jul 2025) |
| Hansoh, first human trial, China (NCT05116410) | 1 | 68 (planned) | Oct 2022 (est.) | Unknown |

Regeneron's first US trial is a small one: its main measures are safety and how much drug is in the blood at weeks 15 and 24, with weight change at week 25 as a secondary measure[12](https://pepvault.app/guides/olatorepatide-explained#source-12). It is the first look at olatorepatide in people outside China. RISE-1, the first Regeneron phase 3, measures weight change at 72 weeks, the length of SURMOUNT-1, the trial behind Zepbound's approval[14](https://pepvault.app/guides/olatorepatide-explained#source-14) [18](https://pepvault.app/guides/olatorepatide-explained#source-18). Hidradenitis suppurativa, the third trial's target, is a skin disease of painful lumps and abscesses in the armpits and groin; that trial enrolls people who also live with overweight or obesity and counts the lumps at 52 weeks[15](https://pepvault.app/guides/olatorepatide-explained#source-15).

Regeneron also plans olatorepatide as the base of combination shots. It said in January 2026 that it would start a program pairing it with Praluent, its LDL cholesterol drug, because GLP-1 drugs alone lower LDL cholesterol by less than 10%[5](https://pepvault.app/guides/olatorepatide-explained#source-5); no such trial is in the registry yet[16](https://pepvault.app/guides/olatorepatide-explained#source-16). Separately, Regeneron tests its muscle antibodies trevogrumab and garetosmab with semaglutide, not with olatorepatide[19](https://pepvault.app/guides/olatorepatide-explained#source-19).

## When is the next olatorepatide data due?

The first US numbers can come first. NCT07431086 has an estimated primary completion of November 13, 2026, and an estimated study completion of December 18, 2026[12](https://pepvault.app/guides/olatorepatide-explained#source-12); Regeneron has not said when it will report it. In China, approval is the next step: the drug's application for long-term weight management was accepted for review by China's drug regulator in June 2026[9](https://pepvault.app/guides/olatorepatide-explained#source-9). Hansoh's two diabetes phase 3 trials estimate March 2027[16](https://pepvault.app/guides/olatorepatide-explained#source-16).

Outside China, the answer is years away. In its October 30, 2026 filing, Regeneron said it expects to start its phase 3 program in obesity without type 2 diabetes in the fourth quarter of 2026 and with type 2 diabetes in the first half of 2027[4](https://pepvault.app/guides/olatorepatide-explained#source-4). The registry estimates that RISE-1's main measurement ends in December 2028[14](https://pepvault.app/guides/olatorepatide-explained#source-14), so a US filing would follow that.

**Has the US trial reported yet?** Not as of November 20, 2026: the registry shows no results, and Regeneron's October filing gives no date[4](https://pepvault.app/guides/olatorepatide-explained#source-4) [12](https://pepvault.app/guides/olatorepatide-explained#source-12). This page is updated when it lands.

<!--promo-->

If you take a weekly GLP-1 today, PepVault logs each shot and reminds you on the day it falls due, so any later switch starts from your own record. [Log it in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-olatorepatide-explained-inline&mt=8)

<!--/promo-->

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. World Health Organization. Proposed INN: List 130 (olatorepatide). WHO Drug Information, Vol. 37, No. 4, 2023. [cdn.who.int](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl130.pdf)
2. Hansoh Pharma. Hansoh Pharma grants Regeneron an exclusive license to its investigational dual GLP-1/GIP receptor agonist HS-20094. June 2, 2025. [hansoh.cn](https://www.hansoh.cn/en/news/news-detail-513935.htm)
3. Regeneron Pharmaceuticals. Quarterly report on Form 10-Q for the quarter ended June 30, 2025 (the Hansoh license). SEC EDGAR. [sec.gov](https://www.sec.gov/Archives/edgar/data/872589/000087258925000019/regn-20250630.htm)
4. Regeneron Pharmaceuticals. Quarterly report on Form 10-Q for the quarter ended September 30, 2026 (olatorepatide milestones). SEC EDGAR. [sec.gov](https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/regn-20260930.htm)
5. Regeneron Pharmaceuticals. J.P. Morgan Healthcare Conference presentation (Form 8-K, Exhibit 99.1). January 12, 2026. [sec.gov](https://www.sec.gov/Archives/edgar/data/872589/000110465926002691/tm262861d1_ex99-1.htm)
6. Hansoh Pharma. Olatorepatide (HS-20094) achieves up to 19.3% weight loss at week 48 in phase 3 study. March 7, 2026. [hansoh.cn](https://www.hansoh.cn/en/news/news-detail-514000.htm)
7. Hansoh Pharma. EASD 2026: phase III (LIGHTEN) data of olatorepatide presented as a late-breaking oral presentation. October 2, 2026. [hansoh.cn](https://www.hansoh.cn/en/news/news-detail-514084.htm)
8. Hansoh Pharma. ObesityWeek 2026: olatorepatide phase III LIGHTEN sex-subgroup data. November 16, 2026. [hansoh.cn](https://www.hansoh.cn/en/news/news-detail-514114.htm)
9. Hansoh Pharma. New drug application for olatorepatide injection accepted by the National Medical Products Administration. June 4, 2026. [hansoh.cn](https://www.hansoh.cn/en/news/news-detail-514034.htm)
10. Hansoh Pharma. 2024 ADA: phase II data of HS-20094 in type 2 diabetes (NCT06118008; poster 733-P). July 3, 2024. [hansoh.cn](https://www.hansoh.cn/en/news/news-detail-513828.htm)
11. ClinicalTrials.gov. NCT06839664: a study of HS-20094 in Chinese adults with overweight or obesity (LIGHTEN). Jiangsu Hansoh Pharmaceutical. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06839664)
12. ClinicalTrials.gov. NCT07431086: olatorepatide in adults with overweight or obesity in the US. Regeneron Pharmaceuticals. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07431086)
13. ClinicalTrials.gov. NCT07685808: olatorepatide with different doses and titration schedules in adults with overweight or obesity. Regeneron Pharmaceuticals. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07685808)
14. ClinicalTrials.gov. NCT07896265: RISE-1, olatorepatide in adults with overweight or obesity without diabetes. Regeneron Pharmaceuticals. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896265)
15. ClinicalTrials.gov. NCT07830329: olatorepatide in moderate to severe hidradenitis suppurativa with overweight or obesity. Regeneron Pharmaceuticals. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07830329)
16. ClinicalTrials.gov. All studies naming olatorepatide or HS-20094, read November 20, 2026. [clinicaltrials.gov](https://clinicaltrials.gov/search?term=olatorepatide%20OR%20HS-20094)
17. Zhao L et al. Tirzepatide for weight reduction in Chinese adults with obesity: the SURMOUNT-CN randomized clinical trial. JAMA. 2024. [PubMed 38819983](https://pubmed.ncbi.nlm.nih.gov/38819983/)
18. Zepbound (tirzepatide) prescribing information. Eli Lilly. DailyMed. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)
19. Regeneron Pharmaceuticals. Fourth quarter and full year 2025 results, with 2026 milestones (Form 8-K, Exhibit 99.1). January 30, 2026. [sec.gov](https://www.sec.gov/Archives/edgar/data/872589/000087258926000004/exhibit991q42025.htm)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · GLP-1

Guide · GLP-1

### [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)

Cagrilintide is a weekly amylin drug, not a GLP-1. What it did alone, what it added to semaglutide in CagriSema's trials, the side effects and FDA status.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [Tirzepatide Studied range: 2.5–15 mg](https://pepvault.app/peptides/tirzepatide)
- [Semaglutide Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/semaglutide)

## Related guides

- Guide · GLP-1s

  ### [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)

  Berobenatide (PF-08653944, MET-097i) is Pfizer's monthly GLP-1 shot in phase 3: how it lasts, every phase 2 number, all 24 trials, and when results are due.

  Read the guide
- Guide · GLP-1s

  ### [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)

  Zenagamtide is amycretin's official name: Novo's one-molecule GLP-1 and amylin drug. The trial results, all 36 registry trials and when phase 3 data is due.

  Read the guide
- Guide · GLP-1s

  ### [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)

  Semaglutide vs tirzepatide side effects in the same trials: nausea, vomiting, reflux, hair loss and injection-site rates side by side, and how many stopped.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Mixing charts

- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)
- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)

### Studies

- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)
- [Semaglutide: 11.85% more weight loss than placebo without diabetes](https://pepvault.app/research/semaglutide-tan-2022)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 31 studies](https://pepvault.app/research#semaglutide)

### Compared with

- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Mazdutide vs Tirzepatide](https://pepvault.app/peptides/compare/mazdutide-vs-tirzepatide)
- [Tirzepatide vs Liraglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-liraglutide)
- [Tirzepatide vs Dulaglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-dulaglutide)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Amino acid](https://pepvault.app/glossary/amino-acid)
- [Receptor agonist](https://pepvault.app/glossary/receptor-agonist)
- [Unit (on a syringe)](https://pepvault.app/glossary/syringe-units)
- [Half-life](https://pepvault.app/glossary/half-life)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)
- [Placebo](https://pepvault.app/glossary/placebo)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
